Forteo

Low Testosterone, Osteoporosis, Osteoporosis + 1 more
Treatment
8 FDA approvals
20 Active Studies for Forteo

What is Forteo

TeriparatideThe Generic name of this drug
Treatment SummaryTeriparatide is a medication manufactured by Eli Lilly and Company that is used to strengthen bones in patients with osteoporosis. It is a form of recombinant human parathyroid hormone, which helps to stimulate bone growth.
Forteois the brand name
image of different drug pills on a surface
Forteo Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Forteo
Teriparatide
2002
4

Approved as Treatment by the FDA

Teriparatide, otherwise called Forteo, is approved by the FDA for 8 uses which include Osteoporosis and Hypogonadism .
Osteoporosis
Helps manage Osteoporosis
Hypogonadism
Helps manage Hypogonadism
Primary Osteoporosis
Helps manage Primary Osteoporosis
Osteoporosis caused by glucocorticoid
Helps manage Osteoporosis caused by glucocorticoid
Osteoporosis
Helps manage Osteoporosis
Osteoporosis
Helps manage Osteoporosis caused by glucocorticoid
Osteoporosis
Helps manage Primary Osteoporosis
Low Testosterone
Helps manage Hypogonadism

Effectiveness

How Forteo Affects PatientsTeriparatide is a synthetic hormone that helps to create new bone in men and women. It increases the amount of bone in your body, increases markers of bone growth, and makes your bones stronger. Taking teriparatide also temporarily increases the amount of calcium in your blood and increases the amount of calcium your body gets rid of in your urine. It can also cause your body to get rid of more phosphorus, which can lead to a drop in phosphorus levels in your blood.
How Forteo works in the bodyParathyroid hormone (PTH) is a hormone that helps to regulate calcium and phosphate levels in the body. Excess PTH can break down bones. Teriparatide is a synthetic form of PTH that works differently from regular PTH. It stimulates new bone growth, rather than breaking down existing bones. It does this by binding to PTH type 1 receptors, which are found on osteoblasts, osteocytes, and kidney cells. This binding triggers pathways in the body that stimulate bone growth and reduce bone breakdown. It also increases the expression of certain proteins that help promote bone growth and decrease proteins that inhibit bone growth.

When to interrupt dosage

The measure of Forteo is contingent upon the diagnosed affliction, including Osteoporosis brought about by glucocorticoid, Osteoporosis and Low Testosterone. The amount also fluctuates as per the technique of delivery (e.g. Subcutaneous or Solution) delineated in the table beneath.
Condition
Dosage
Administration
Low Testosterone
, 0.25 mg/mL, 0.75 mg/mL, 2.0 mg/mL
Subcutaneous, Solution - Subcutaneous, Solution, , Injection, solution, Injection, solution - Subcutaneous
Osteoporosis
, 0.25 mg/mL, 0.75 mg/mL, 2.0 mg/mL
Subcutaneous, Solution - Subcutaneous, Solution, , Injection, solution, Injection, solution - Subcutaneous
Osteoporosis
, 0.25 mg/mL, 0.75 mg/mL, 2.0 mg/mL
Subcutaneous, Solution - Subcutaneous, Solution, , Injection, solution, Injection, solution - Subcutaneous
Osteoporosis
, 0.25 mg/mL, 0.75 mg/mL, 2.0 mg/mL
Subcutaneous, Solution - Subcutaneous, Solution, , Injection, solution, Injection, solution - Subcutaneous

Warnings

There are 20 known major drug interactions with Forteo.
Common Forteo Drug Interactions
Drug Name
Risk Level
Description
Acetohexamide
Minor
The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Teriparatide.
Carbutamide
Minor
The therapeutic efficacy of Carbutamide can be decreased when used in combination with Teriparatide.
Chlorpropamide
Minor
The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Teriparatide.
Glibornuride
Minor
The therapeutic efficacy of Glibornuride can be decreased when used in combination with Teriparatide.
Gliclazide
Minor
The therapeutic efficacy of Gliclazide can be decreased when used in combination with Teriparatide.
Forteo Toxicity & Overdose RiskThe lethal dose of teriparatide when given subcutaneously or intravenously in rats is 1000µg/m3 and 300µg/m3, respectively. In rare cases, people have accidentally been given 40 times the recommended dose of 800mcg, which resulted in nausea, weakness, lethargy, and low blood pressure. As there is no antidote for an overdose, treatment should involve stopping the teriparatide and monitoring calcium and phosphorus levels in the blood, as well as providing supportive measures such as hydration.
image of a doctor in a lab doing drug, clinical research

Forteo Novel Uses: Which Conditions Have a Clinical Trial Featuring Forteo?

62 active studies are being conducted to assess the potential of Forteo to alleviate Osteoporosis, Low Testosterone and related Osteoporotic conditions.
Condition
Clinical Trials
Trial Phases
Osteoporosis
27 Actively Recruiting
Not Applicable, Phase 4, Phase 1, Phase 3, Phase 2
Low Testosterone
6 Actively Recruiting
Phase 4, Phase 2, Phase 1
Osteoporosis
0 Actively Recruiting
Osteoporosis
0 Actively Recruiting

Forteo Reviews: What are patients saying about Forteo?

5Patient Review
6/3/2019
Forteo for Decreased Bone Mass Following Menopause
I was so pleased with the results of this treatment. It not only repaired my broken bones, but it also strengthened the surrounding areas to prevent any future breakage.
4.7Patient Review
3/31/2019
Forteo for Osteoporosis in Male Patient
The injection was simple, but I experienced stomach cramps about 20 minutes later.
4Patient Review
4/19/2021
Forteo for osteoporosis in postmenopausal woman at high risk for fracture
I've had no issues with side effects and the needle injections are really not that bad. After one year of treatment, I saw a significant improvement in my bone density test results. Hoping for similar results this coming May from my second-year tests.
3.7Patient Review
11/30/2020
Forteo for Decreased Bone Mass Following Menopause
I took this medication for 18 months before I stopped. I gained weight while on it, but eventually got tired of having to inject myself daily. I then switched to Evista for a couple years, which helped me lose the weight again. However, now that I'm back on Forteo (for the final 6 months that my insurance will cover), I've been having problems with my memory. Not sure if it's related to the drug or not...
3Patient Review
7/8/2020
Forteo for Decreased Bone Mass Following Menopause
I am on my fourth month of Forteo for osteoporosis prevention. So far, no fractures or broken bones. I walk 4 miles several times a week and don't have any other health issues. However, by the third month, I started feeling occasional nausea which quickly became constant fatigue. I messaged my doctor and will now inject every other day to see if I can tolerate it better. My non-fasting lab showed elevated glucose of 145 which is new for me.
3Patient Review
4/22/2020
Forteo for osteoporosis in postmenopausal woman at high risk for fracture
I've been using Forteo for a year now. My L spine was -3.7 a year ago and it's only at -3.1 now, which isn't that great of an improvement. My femur went from -1.5 to -2.4, so there hasn't been much progress there either unfortunately..
2.7Patient Review
7/27/2020
Forteo for Decreased Bone Mass Following Menopause
Since beginning this treatment, I've experienced an increase in pain and nausea with each injection. I'm now trying to every third day in order to try and get some benefit for my bones. The side effects are really taking a toll though.
2.3Patient Review
2/14/2019
Forteo for Osteoporosis in Male Patient
I did not experience any benefits from this medication, and unfortunately about three months after starting the shots I lost a tooth. Be aware of the potential side effects before trying this treatment.
2Patient Review
9/6/2022
Forteo for Osteoporosis in Male Patient
After just a few doses, I started having excruciating pain in my knee and leg. It got so bad that I couldn't walk without assistance. Needless to say, I stopped taking the medication and feel like I wasted a ton of money. Now, I don't know what to do about my osteoporosis.
1.7Patient Review
11/11/2022
Forteo for osteoporosis in postmenopausal woman at high risk for fracture
The last unit I received was defective, and when I contacted the company they gave me a run-around rather than taking responsibility. It's hard enough to use this product as it is; having to deal with customer service on top of that is really frustrating.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about forteo

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the dangers of Forteo?

"One common side effect of this medication is feeling faint, tired, or confused."

Answered by AI

Is Forteo a daily injection?

"Forteo is typically given as a single daily injection beneath the skin. A common dosage is 20 micrograms (mcg) once per day."

Answered by AI

Does Forteo build bone?

"Forteo is a medication used to treat osteoporosis. It is a synthetic version of the human parathyroid hormone, which promotes the growth of new bone. Other osteoporosis medications work by inhibiting bone resorption, or breakdown."

Answered by AI

What does the drug Forteo do?

"Forteo (teriparatide injection) can reduces your risk of another fracture. It is a prescription medicine used to treat postmenopausal women who have osteoporosis who are at high risk for having broken bones (fractures) or who cannot use other osteoporosis treatments."

Answered by AI

Clinical Trials for Forteo

Image of ICON Early Phase Services, LLC_Clinic San Antonio in San Antonio, United States.

Follitropin Alfa for Male Infertility

18 - 45
Male
San Antonio, TX
The purpose of this study is to assess the bioequivalence of Test and Reference in healthy downregulated male participants. This is a 2-sequence, 2-period study using the following treatment sequences across Study Periods 1 and 2. At the end of the first Downregulation period (DR1), eligible participants will be randomly assigned to 1 of the 2 treatment sequences: Sequence 1: Test - Reference Sequence 2: Reference - Test Where, Test = follitropin alfa (solution for injection in prefilled pen), and Reference = follitropin alfa (powder and diluent for solution for injection in vial). The total duration of the study will be up to approximately 9 weeks.
Phase 1
Recruiting
ICON Early Phase Services, LLC_Clinic San AntonioMedical ResponsibleEMD Serono Research & Development Institute, Inc.
Image of University of Maryland, Baltimore, Department of Epidemiology and Public Health, Division of Gerontology in Baltimore, United States.

OPTIONS Program for Osteoporosis

65+
All Sexes
Baltimore, MD
Osteoporosis is a disease that weakens bones so the bones may break easily. The risk for osteoporosis increases with age in both women and men. Osteoporosis affects 10 million older adults in the US. Osteoporosis is a common cause of broken bones in the hips and legs. Broken bones can lead to disability, nursing home placement, and death. Because of the dire consequences, a broken hip or leg is one of the most dreaded injuries for older adults. Many studies confirm that a simple regimen of exercise, healthy diet and bone-strengthening medications can improve overall recovery after a broken hip or leg. This regimen can prevent a person from becoming disabled, having future fractures, and even prevent death. Many older adults have surgery in a hospital after breaking a hip or leg. Then older adults go to a skilled nursing facility (SNF) for rehabilitation. Care in SNFs varies greatly. Some patients do not receive the regimen that the investigators know is most beneficial to improve bone health and recovery. Even patients who get exercise, healthy diet, and bone-strengthening medication in the SNF, may not continue with the regimen once patients go home. Therefore, the investigators want to implement and test OsteoPorotic fracTure preventION System (OPTIONS). OPTIONS is a program that will integrate the regimen into the care that is provided in SNFs and after discharge to the community. OPTONS will provide information about exercise, diet, and bone-strengthening medication. OPTIONS will provide doctors, clinical staff, patients, and care partners with the information these stakeholders need to carry out the best-practice regimen. The investigators are partnering with PointClickCare, a large cloud-based healthcare software provider, with SNFs and community care sites across the US. The investigators will include 32 SNFs from different US areas. The investigators will flip a coin to assign SNFs to the intervention (OPTIONS) or the control arm (enhanced usual care) of the study. Enhanced usual care is the care that is typically provided in SNFs after a fracture and adding information about a publicly available fall prevention toolkit. The investigators are using an "implementation science" approach that requires the investigators to get input from the OPTIONS study's vast stakeholder community throughout the study. The OPTIONS study's stakeholders include patients, care partners, clinicians, and professional organizations. The research question is, can using OPTIONS in SNFs and in the community after discharge improve physical function and quality of life in older people in the year after a hip or leg fracture? The investigators are measuring patient-reported outcomes. The investigators will include 1553 patients across the 32 facilities. The investigators have selected outcomes that are important to patients. Specifically, the investigators are measuring patient-reported function and quality of life. The investigators are also measuring patient-reported falls and fractures. The investigators will track the number of patients who die during the study. This study's hypothesis is that patients who receive OPTIONS will report better physical function (i.e., can walk and take better care of themselves) than those who receive enhanced usual care. The investigators also hypothesize that patients that receive OPTIONS will report a better quality of life than those who receive enhanced usual care. This study will provide sound data about the effectiveness of OPTIONS. OPTIONS could then be spread to other SNFs and community-based programs. This would ensure that all older people receive the right care after a hip or leg fracture.
Waitlist Available
Has No Placebo
University of Maryland, Baltimore, Department of Epidemiology and Public Health, Division of Gerontology (+1 Sites)Denise Orwig, PhD
Have you considered Forteo clinical trials? We made a collection of clinical trials featuring Forteo, we think they might fit your search criteria.Go to Trials
Image of Neuromuscular Research Laboratory in Pittsburgh, United States.

Hormone Therapy for Musculoskeletal Health

18 - 40
All Sexes
Pittsburgh, PA
Non-combat-related muscle, tendon and bone injuries are the most common injuries suffered by military personnel, particularly in new recruits. These injuries impact military readiness and are responsible for roughly 60% of limited duty days, 65% of soldiers who are unable to deploy, and nearly $500 million in medical cost to the government annually in the Army alone. Drug interventions must be studied and developed to prevent these negative outcomes and prepare military personnel for the demands of military service. At the current time, military leadership has identified critical gaps in understanding how to minimize these injuries and train soldiers with drug intervention serving among those gaps. The goal of this study is to determine how a hormonal intervention can change muscle, tendon, and bone function as well as physical and psychological performance in response to mental and physical stress. To do so, we will examine sex hormone (testosterone, estrogen) levels, muscle, tendon, and bone images, blood samples, and physical and mental performance. We will look at things like changes in hormone levels, chemicals released from active skeletal muscles, and your body composition. The results from this study will be used to improve physical readiness training in the military with the goal of reducing injuries.
Phase 4
Recruiting
Neuromuscular Research LaboratoryBradley C Nindl, PhD
Have you considered Forteo clinical trials? We made a collection of clinical trials featuring Forteo, we think they might fit your search criteria.Go to Trials
Image of Marcus Institute for Aging Research, Hebrew SeniorLife in Boston, United States.

Injury Prevention Care Models for Osteoporosis

65+
All Sexes
Boston, MA
The goal of this clinical trial is to compare three care models for optimizing medications and preventing falls with broken bones in patients receiving rehabilitation after a hospitalization for a broken bone. The primary outcome is injurious falls, with secondary outcomes measuring how the process of care is changed and capturing patient-reported outcomes valued by stakeholders. The main questions this study aims to answer are: * Which of the three models is more effective in preventing falls with fractures? * What are the differences in patient-centered outcomes amongst the three models? These include pain, depression, anxiety, sleep, medication side effect burden, and fear of falling. * What are the differences in osteoporosis treatment and medication burden? The three care models are: a Deprescribing Care Model designed to reduce or stop fall-related medications, a Bone Heath Service Model designed to provide osteoporosis evaluation and management, and an Injury Prevention Service Model offering both services. 42 SNFs will participate in this study. The three models will be incorporated into the routine care of patients at these facilities who are receiving rehabilitation after a hospitalization for a fracture. All care models will be delivered remotely to patients in the SNF and after they transition home by a post-fracture nurse consultant supported by an interprofessional team. This study has three aims. See Detailed Description for more details. This ClinicalTrials.gov record represents the Comparative Effectiveness Aim of the protocol.
Waitlist Available
Has No Placebo
Marcus Institute for Aging Research, Hebrew SeniorLife (+1 Sites)Cathleen S Colon-Emeric, MD, MHS
Image of University of Saskatchewan in Saskatoon, Canada.

Milk + Yogurt for Bone Health

19 - 30
All Sexes
Saskatoon, Canada
Milk and dairy products contain significant amounts of nutrients that contribute to optimal health - nutrients like calcium, vitamin D, and high-quality protein. Fermented milk products or fermented dairy products are dairy foods that have been fermented with certain bacteria. Yogurt is a fermented dairy product containing millions of beneficial bacteria. In this study, the invesgitagtors will look at the effect of milk (a non-fermented dairy product) and yogurt (a fermented dairy product) supplementation on bone health and the amount of fat and muscle mass in Canadian young adults over a 24-month period. While dairy products contain significant amounts of nutrients, the scientific community does not know the impact of long-term supplementation of fermented (i.e., yogurt) or non-fermented (i.e., milk) dairy food on bone health and the amount of fat and muscle mass in young adults. To fill this knowledge gap, the investigators will recruit participants with low calcium intake and assign them to three different groups: 1) milk (intervention) group; 2) yogurt (intervention) group; and 3) control group. The investigators will ask the participants in the milk group to drink 1.5 servings (375 mL) of milk per day for 24 months. Participants in the yogurt group will consume 2 servings (350 g) of yogurt per day for 24 months. Those in the control group will continue their usual diets. Using a randomized controlled trial design, the investigators will measure bone health parameters, hormonal indices related to bone metabolism, body composition (e.g., muscle mass, fat mass), and the number and composition of bacteria living in the gastrointestinal (GI) tract. The hypothesis is that supplementation with yogurt will have more positive effects on bone health indices, particularly femoral neck BMD as the primary outcome, than milk in Canadian adults aged 19-30 years. The secondary hypothesis is that supplementation with yogurt, as a fermented milk product, will have a more beneficial effect than milk on body composition measures. The data will provide valuable information for developing targeted health initiatives and marketing strategies regarding the benefits of fermented and non-fermented dairy product consumption.
Recruiting
Has No Placebo
University of SaskatchewanPhil Chilibeck, PhD
Image of University of Kentucky in Lexington, United States.

Teriparatide vs Alendronate for Osteoporosis

18+
Female
Lexington, KY
Osteoporosis is a health problem of major proportions. It affects more than 40 million Americans and results in more than 2 million fractures annually among Medicare patients alone. Hospital admissions for osteoporotic fractures exceed those of heart attacks, strokes and breast cancer combined. Osteoporosis is commonly considered a disease associated with menopause. This estrogen deficiency related bone loss is characterized by high bone turnover with increased resorption without commensurate changes in bone formation. It is in contrast to age-related bone loss, which starts as early as in the fourth decade of life and continues with increasing age. Age-related bone loss is usually associated with lower bone turnover and decreased bone formation is the main abnormality. Current therapies do not address age-related bone loss and the special needs of the age-related osteoporosis population is currently ignored. This is to a great degree due to difficulties associated with the bone biopsy necessary for unequivocal determination of bone turnover status. Thus, the current standard of care relies on starting with an antiresorber, which is of limited effectiveness in age-related osteoporosis, and in fact impedes the effectiveness of the appropriate anabolic medication. In a current ongoing study - Novel precision medicine approach to treatment of osteoporosis based on bone turnover. EIRB#70781; efforts are focused on addressing this particular problem. Our follow-up study seeks to achieve one specific aim: to compare effectiveness of Alendronate vs Teriparatide after participants have been switched at the end of treatment at year one, to the other drug at year two for the same duration of treatment.
Phase 4
Waitlist Available
University of KentuckyPaul Netzel, DNP
Have you considered Forteo clinical trials? We made a collection of clinical trials featuring Forteo, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security